News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Medical Genome Reference Bank Uses Whole-Genome Sequencing to Add 4,000 Healthy Older Adults to Its Huge Database

The resulting genomic dataset may provide useful diagnostic insights that can be used by clinical laboratory and pathology professionals to learn how and why some people age with good health

Why do some seniors age in good health and other seniors suffer with multiple chronic conditions? A new genetic database is using whole-genomic sequencing (WGS) to answer that question in ways that may benefit medical laboratories.

Because of the rapid aging of populations in the United States and other developed nations throughout the world, there is keen interest in how to keep seniors healthy. In fact, developing effective lab testing services in support of improved senior health is one of the big opportunities for both clinical laboratories and anatomic pathology groups.

Until recent years, most clinical pathologists dealt primarily with lab tests that used specimens such as blood and urine. However, genetics researchers are using WGS to discover new causes for many chronic illnesses. And the tools these researchers are developing offer pathologists and clinical laboratories powerful new ways to help doctors diagnose disease.

One genetics study involved a collaboration between the Garvan Institute of Medical Research at the University of New South Wales (UNSW) and Monash University. The research, launched in 2012, resulted in a database called the Medical Genome Reference Bank (MGRB).

Through the use of WGS, the MGRB now features a huge database of thousands of healthy elderly people. The data it contains may enable pathology scientists to learn, from a genetic standpoint, why some people age healthfully while others do not.

The researchers published their work titled, “The Medical Genome Reference Bank: A Whole-Genome Data Resource of 4,000 Healthy Elderly Individuals. Rationale and Cohort Design,” in the European Journal of Human Genetics.

Finding New Applications for Genetic Data

According to the UNSW published study, “The MGRB is comprised of individuals consented through the biobank programs of two contributing studies … Each sample is from an individual who has lived to [greater than or equal to] 70 years with no reported history or current diagnosis of cardiovascular disease, dementia, or cancer, as confirmed by the participating studies at recent follow-up study visits.”

The researchers noted in their paper, “Aged and healthy populations are more likely to be selectively depleted of pathogenic alleles, and therefore particularly suitable as a reference population for the major diseases of clinical and public health importance.”

The MGRB plans to make its database openly accessible to the international research community through its website once all 4,000 samples have been sequenced. Currently, about 3,000 of the samples have been analyzed, as noted on the Garvan website, which is tracking the MGRB’s progress.


“The Medical Genome Reference Bank can tell us much about what it means to grow old but remain well, and is a powerful tool to help us deconstruct the genetics of common diseases,” said David Thomas, PhD (above), an NHMRC Principal Research Fellow, Director of The Kinghorn Cancer Center, and Head of the Cancer Division of the Garvan Institute in New South Wales, AU, in a statement reported by GenomeWeb. (Photo copyright: South West Sydney Research.)

Personal Genetic Data in Precision Medicine

“The integration of genomic knowledge and technologies into healthcare is revolutionizing the way we approach clinical and public health practice,” Caron M. Molster, et al, noted in, “The Evolution of Public Health Genomics: Exploring Its Past, Present, and Future,” published in Frontiers in Public Health. Molster is Manager at the Health Department Western Australia in Perth, and lead author of the paper.

“Public health genomics has evolved to responsibly integrate advancements in genomics into the fields of personalized medicine and public health,” the researchers wrote.

The 100,000 Genomes Project in the United Kingdom is sequencing the genomes of people who have rare diseases and their families. Researchers all over the world are collecting genomic data with plans to use it in different ways, and on various chronic disease populations, in pursuit of precision medicine goals.

Molster and her co-authors noted the comparable development of genetic sequencing and precision medicine in their paper.

“Parallel to the developments in precision medicine has been the advancement of technologies that enable the production, aggregation, analysis, and dissemination of extremely large volumes of individual- and population-level data on genes, environment, behavior, and other social and economic determinants of health. These data have proven useful in finding new correlations, patterns and trends, particularly those involving complex interactions, in relation to diseases, pathogens, exposures, behaviors, susceptibility (risk), and health outcomes in populations,” they wrote.

According to Paul Lacaze, PhD, Head of the Public Health Genomics Program at Monash University, one of the challenges in interpreting whole-genome data in order to diagnose disease is “discriminating rare candidate disease-causing variants from the large numbers of benign variants unique to each individual. Reference populations are powerful filters,” he noted in the MGRB paper.

The MGRB database provides just such a powerful reference population, giving researchers who are studying specific diseases a tool for comparison.

Other Studies into Heathy Aging

Other initiatives to create datasets of genome information for specific populations also are underway. The Scripps Translational Science Institute (STSI) in La Jolla, Calif., has been studying healthy aging since 2007. That’s when STSI launched the Wellderly Study, according to a news release. As of 2016, they had sequenced the genomes of 600 study participants, as well as 511 samples for comparison from a study being conducted separately by the Inova Translational Medicine Institute, a paper in Nature noted.

Another effort being conducted in China involves a database called PGG.Population. These researchers seek to “create a comprehensive depository of geographic and ethnic variation of human genome, as well as a platform bringing influence on future practitioners of medicine and clinical investigators,” according to their 2018 paper published in Nucleic Acids Research.

In this case, rather than identifying common genomic variants among a specific population, such as the healthy elderly, the researchers are working to understand how genetic variations are distributed among specific populations. “The PGG.Population database documents 7,122 genomes representing 356 global populations from 107 countries and provides essential information for researchers to understand human genomic diversity and genetic ancestry,” wrote the researchers.

Each of these disparate datasets represents paths of investigation that could lead to a better understanding of personal and public health. As technologies continue to develop that enable scientists to sift through the massive amount of WGS data being generated, a clearer picture of what healthy aging at the genetic level looks like will likely emerge.

Precision medicine is leading to precision public health, and clinical pathology laboratories are important parts of the public health puzzle.

—Dava Stewart

Related Information:

Genome Sequencing Data from Thousands of Healthy Elderly People Now Available  

The Medical Genome Reference Bank: A Whole-Genome Data Resource of 4000 Healthy Elderly Individuals. Rationale and Cohort Design

The Evolution of Public Health Genomics: Exploring Its Past, Present, and Future

Wellderly Study Suggests Link Between Genes That Protect Against Cognitive Decline and Overall Healthy Aging

Pathologists Performing Molecular Autopsy in Cases of Sudden Unexpected Death Could Identify Genetic Clues That Help Surviving Family Members Assess Their Own Risk

Pathologists could benefit if postmortem genetic testing becomes more commonplace following incidents of sudden unexpected death

Pathologists are discovering that molecular autopsy, also called postmortem molecular testing, could boost the chance of discovering the likely or plausible cause of sudden unexpected death, according to preliminary results from a study published in the Journal of the American Medical Association (JAMA).

Researchers led by Ali Torkamani, PhD, Director of Genome Informatics at the Scripps Translational Science Institute (STSI) and Assistant Professor of Molecular and Experimental Medicine at the Scripps Research Institute, sequenced samples from 25 sudden death cases. They identified: (more…)

Consumers Increasingly Purchase Medical Laboratory Self-Test Kits for Blood Glucose, Cholesterol, and Colon Cancer Screening, according to Consumer Reports

The self-monitoring/self-test market is expected to swell to $19 billion by 2019, offering opportunities for pathologists and clinical laboratories to advise patients and ensure the proper use of home tests

Might the future of clinical laboratory tests be sitting on the shelf at your corner pharmacy right now? Patient self-testing and screening kits continue to garner the approvals of Consumer Reports’ medical advisors.

That’s happening because the Food and Drug Administration (FDA) continues to clear many do-it-yourself tests that traditionally were performed in medical laboratories by qualified personnel, much to the chagrin of some doctors.

Empowered healthcare consumers are checking their cholesterol, monitoring their diabetes, and more, using health screening kits that range from $8 to $175, according to a Consumer Reports on Health article, which advised consumers to use self-tests judiciously and share the results with their physicians. (more…)

Finding Genomes with ‘Knockout’ Genes Leads to Development of New Therapeutic Drugs, along with Clinical Laboratory Tests for these Biomarkers

Drugs based on knockout genes are expected to trigger the need for companion diagnostic tests that will be performed by pathologists and medical laboratory scientists

Pharmaceutical companies and other research programs are developing a new opportunity to use information from human genome sequencing to create a new class of therapeutic drugs. These drugs target “knockout genes” and those same genes are expected to be used as diagnostic biomarkers for clinical laboratory testing as a new field of companion diagnostics emerges.

In simplest terms, large-scale DNA sequencing of the human genome is enabling researchers to identify individuals with “knockout” genes and then develop therapeutic drugs based on that knowledge.

The first commercial success story from this partnership of geneticists and the pharmaceutical industry is expected to be a new class of drugs that lowers cholesterol. These drugs may reach pharmacy shelves this year, reported an October 24 Nature article. (more…)

Scanadu is Preparing Consumer Self-Test Device for Review by the FDA as Part of Its Mission to Enable Patients to Monitor Their Health without the Need for Clinical Pathology Laboratory Tests

Scanadu’s device is called the ScanaFlo and is designed to collect biometric data from consumers using a variety of methods, including urine specimens

Now gathering study data needed to launch a review by the Food and Drug Administration (FDA) is a low-cost lab urinalysis device that returns results via a smartphone for conditions such as pregnancy and diabetes. More significant for pathologists and clinical laboratory executives, this handy point-of-care device is capable of doing tests for traditional medical laboratory tests, ranging from glucose and leukocytes to bilirubin and creatinine.

The device was invented at Scanadu, Inc., a health-tech startup based at NASA Ames Research Center in Mountain View, California. It is a new low-cost lab urinalysis kit that uses a smartphone to return test results on liver, kidneys, urinary tract, and metabolic functions. The company uses imaging and sound analysis, molecular diagnostics, data analytics, and a suite of algorithms to create devices that offer consumers comprehensive, real-time health data on mobile devices. (more…)

;